Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management

被引：43
|
作者：
Savoia, Paola [1 ,2 ]
Astrua, Chiara [1 ]
Fava, Paolo [1 ]
机构：
[1] Univ Turin, Dept Med Sci, Turin, Italy
[2] A Avogadro Univ Eastern Piedmont, Dept Hlth Sci, Novara, Italy
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2016年 / 12卷 / 05期
关键词：
anti-CTL-A4; ipilimumab; immunotherapy; melanoma treatment; toxicity; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; T-CELL RESPONSES; RECOMBINANT INTERLEUKIN-2 THERAPY; PRETREATED ADVANCED MELANOMA; EXPANDED ACCESS PROGRAM; CTLA-4; BLOCKADE; BRAIN METASTASES; PHASE-2; TRIAL; ADVERSE EVENTS; DOUBLE-BLIND;
D O I：
10.1080/21645515.2015.1129478
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
In the last years the onset of new therapies changed the management of malignant melanoma. Anti CTLA-4 antibody ipilimumab was the first drug to achieve a significant improvement in survival of advanced stage melanoma. This new therapeutic agent is characterized by a number of side effects that are totally different from those of traditional chemotherapy, mainly caused by the immune system activation. The purpose of this paper is to underline the central role of ipilimumab in the treatment of metastatic melanoma and to characterize related adverse events in terms of incidence, duration and severity of presentation. The early recognition of these side effects is crucial in order to ensure an appropriate management of the toxicities, thus reducing the long term clinical sequelae and the inappropriate treatment discontinuation.
引用
收藏
页码：1092 / 1101
页数：10
相关论文
共 50 条
  • [1] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [2] Anti-CTLA-4 antibodies A major therapeutic advance in metastatic melanoma treatment
    Robert, Caroline
    Mateus, Christine
    M S-MEDECINE SCIENCES, 2011, 27 (10): : 850 - 858
  • [3] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    Bowyer, S.
    Prithviraj, P.
    Lorigan, P.
    Larkin, J.
    McArthur, G.
    Atkinson, V.
    Millward, M.
    Khou, M.
    Diem, S.
    Ramanujam, S.
    Kong, B.
    Liniker, E.
    Guminski, A.
    Parente, P.
    Andrews, M. C.
    Parakh, S.
    Cebon, J.
    Long, G. V.
    Carlino, M. S.
    Klein, O.
    BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
  • [4] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    S Bowyer
    P Prithviraj
    P Lorigan
    J Larkin
    G McArthur
    V Atkinson
    M Millward
    M Khou
    S Diem
    S Ramanujam
    B Kong
    E Liniker
    A Guminski
    P Parente
    M C Andrews
    S Parakh
    J Cebon
    G V Long
    M S Carlino
    O Klein
    British Journal of Cancer, 2016, 114 : 1084 - 1089
  • [5] The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
    Voskens, Caroline J.
    Goldinger, Simone M.
    Loquai, Carmen
    Robert, Caroline
    Kaehler, Katharina C.
    Berking, Carola
    Bergmann, Tanja
    Bockmeyer, Clemens L.
    Eigentler, Thomas
    Fluck, Michael
    Garbe, Claus
    Gutzmer, Ralf
    Grabbe, Stephan
    Hauschild, Axel
    Hein, Ruediger
    Hundorfean, Gheorghe
    Justich, Armin
    Keller, Ullrich
    Klein, Christina
    Mateus, Christine
    Mohr, Peter
    Paetzold, Sylvie
    Satzger, Imke
    Schadendorf, Dirk
    Schlaeppi, Marc
    Schuler, Gerold
    Schuler-Thurner, Beatrice
    Trefzer, Uwe
    Ulrich, Jens
    Vaubel, Julia
    von Moos, Roger
    Weder, Patrik
    Wilhelm, Tabea
    Goeppner, Daniela
    Dummer, Reinhard
    Heinzerling, Lucie M.
    PLOS ONE, 2013, 8 (01):
  • [6] Neutropenia in a Patient Treated With Ipilimumab (anti-CTLA-4 Antibody)
    Akhtari, Mojtaba
    Waller, Edmund K.
    Jaye, David L.
    Lawson, David H.
    Ibrahim, Ramy
    Papadopoulos, Nicholas E.
    Arellano, Martha L.
    JOURNAL OF IMMUNOTHERAPY, 2009, 32 (03) : 322 - 324
  • [7] Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma
    Sarnaik, Amod A.
    Weber, Jeffrey S.
    CANCER JOURNAL, 2009, 15 (03): : 169 - 173
  • [8] Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
    Kaehler, Katharina C.
    Hassel, Jessica C.
    Heinzerling, Lucie
    Loquai, Carmen
    Moessner, Rotraut
    Ugurel, Selma
    Zimmer, Lisa
    Gutzmer, Ralf
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 (07): : 662 - 681
  • [9] Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: Recent findings
    Lens, Marko
    Ferrucci, Pier F.
    Testori, Alessandro
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2008, 3 (02) : 105 - 113
  • [10] Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
    Simeone, Ester
    Ascierto, Paolo A.
    JOURNAL OF IMMUNOTOXICOLOGY, 2012, 9 (03) : 241 - 247
12345